Knisley, M. Pharmacogenomics in the nursing literature: An integrative review. Nursing Outlook, 62 4 , The researchers were addressing the state of pharmacogenomics, a branch of medical science, in the nursing literature. In this case, the researchers critically examined the concepts of pharmocogenetics and pharmacogenomics in nursing, pharmacogenomics applications in clinical practice and the responsibilities of nurses in applying these concepts. The researchers used computer-based searching methods to identify nursing literature in the existing online libraries PubMed, Ovid Nursing and the Cumulative Index to Nursing and Allied Health.
Pharmacogenomics of COVID therapies — [email protected]
Background: The pathophysiology of keloid scars is still not fully understood and a universally reliable effective treatment has not been identified. Pharmacogenetics explores how drug response to a particular therapy can relate to genetic variations. Purpose: To investigate how pharmacogenetics could be applied to keloid scars and the relevance of this to clinical practice. Methods: We reviewed the literature and discuss our current knowledge of pharmacogenomics in the treatment of keloid scars. A literature search was performed using the terms 'Pharmacogenetics', 'Pharmacogenomics', 'Keloid' and 'Scar'.
The role of pharmacogenetics in keloid scar treatment: A literature review
Its etiopathogenesis is unknown, although genetic causes have been postulated. Materials and methods: This review analyzed articles published to date that have studied genetic factors associated with ONJ. Fifteen case-control studies were included, published between and Results: Five set out to determine genetic causes by means of genome-centered techniques, while ten do so by investigating gene-centered variants. Nine works found statistically significant associations between one or various single nucleotide polymorphisms SNPs and the appearance of ONJ.
An impressive and ever-expanding research literature exists on the topic of pharmacogenomics. Despite this, only four genes have been vetted as clinically actionable. Expert consensus publications and editorials from thought leaders in psychiatry in the past 3 years have consistently concluded that psychiatric pharmacogenomic panels AKA combinatorial pharmacogenetic tests are not currently evidence based, and clinical decisions should not be based on their reports. For example, the FDA is aware of genetic tests that claim results can be used to help physicians identify which antidepressant medication would have increased effectiveness or side effects compared to other antidepressant medications.